APTA Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative therapies for diseases associated with regulatory autoantibodies, is strengthening its management team with the addition of Dr. Daniel Bock as CSO/COO.
Dr. Daniel Bock brings over 25 years of pharmaceutical R&D expertise, spanning early drug discovery to clinical development, with a focus on immunomodulatory drugs, including small molecules and oligonucleotides. He worked at Novartis before joining and building up Revotar Biopharmaceuticals, serving in different roles, ultimately as CSO. Alongside ongoing consultancy in the biotech space, he was most recently CSO at sterna biologicals.
Dr. Oliver von Stein, Chief Executive Officer of APTA Therapeutics, commented:
“We are very honored to have Dr. Bock join the management team of APTA Therapeutics at this early stage. Providing comprehensive drug development knowledge combined with strategic operational skills he will play a key role in the company’s development. We look forward to working with him in the years ahead.”
“I am excited to be joining APTA Therapeutics to support evaluation of rovunaptabin and contribute to strengthening the company’s pipeline,” added Dr. Bock.